programme - ESE Basic Endocrinology Course

programme - ESE Basic Endocrinology Course

ESE BASIC SCIENCE COURSE
ENDOCRINE
AND NEUROENDOCRINE
CANCER:
BEYOND STRUCTURAL GENETIC
ALTERATIONS OF ONCOGENES AND
TUMOUR SUPPRESSOR GENES
17-19 FEBRUARY, 2016
HOSPITAL STO ANTÓNIO
PORTO / PORTUGAL
programme
Wednesday, February 17th
ESE Basic Science Course
Endocrine and
Neuroendocrine Cancer:
BEYOND STRUCTURAL GENETIC ALTERATIONS OF ONCOGENES
ANDTUMOUR SUPPRESSOR GENES
12.00 Registration
14.00 Welcome session
M. Sobrinho Simões (Porto, Portugal)
SESSION 1 - THYROID TUMOURS
Chairs: José Manuel Cameselle Teijeiro (Santiago de Compostela, Spain),
M. João Oliveira (Porto, Portugal)
14.30 Advances in molecular pathogenesis of thyroid cancer
Pilar Santisteban (Madrid, Spain)
15.00 Metabolic alterations in thyroid cancer cells
Valdemar Máximo (Porto, Portugal)
15.30
TERT promoter mutations in thyroid cancer: beyond immortalization?
Paula Soares (Porto, Portugal)
16.00 coffee-break
Chairs: Garcilaso Riesco-Eizaguirre (Madrid, Spain),
M. Sobrinho Simões (Porto, Portugal)
16.30 Molecular targeted therapy in medullary
and well-differentiated thyroid carcinoma
Valeriano Leite (Lisbon, Portugal)
17.00 Oral Communications
OC1 A new chemotherapy combination (U0126+SN50) potentiates apoptosis
in thyroid cancer but induced survival in normal thyroid
Rodrigues J, Garcia-Rendueles A, Garcia-Rendueles M, Suarez Fariña M, Perez-Romero S,
Bernabeu I, Rodriguez-Garcia J, Fugazzola L, Sakai T, Liu F, Cameselle-Teijeiro J, Bravo S,
Alvarez C
OC2
mTOR pathway activation in papillary thyroid carcinomas:
associations and correlations
Tavares C, Coelho M, Melo M, Rocha A, Pestana A, Batista R, Salgado C, Eloy C, Rios E,
Ferreira L, Sobrinho-Simões M, Soares P
17.30 Endocrine cancer: in the light of recent molecular studies
Barbara Jarzab (Gliwice, Poland)
18.00 The European Task Group for Endocrine Cancers «ETEC»
19.00 Welcome reception
Thursday, February 18th
SESSION 2 - NEUROENDOCRINE TUMOURS
Chairs: Barbara Jarzab (Gliwice, Poland), Lúcio Santos (Porto, Portugal)
9.00
The genomic landscape of neuroendocrine tumours:
The International Cancer Genome Consortium
Aldo Scarpa (Verona, Italy)
9.30 From molecules to treatment: the research-derived therapeutic
landscape in NETs
Marianne Pavel (Berlin, Germany)
10.00 Oral Communications
OC3 SESSION 3 - ADRENOCORTICAL TUMOURS
PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Chairs: Mercedes Robledo (Madrid, Spain), Duarte Pignatelli (Porto, Portugal)
14.30 New insights on adrenocortical tumours OMICs
Jerome Bertherat (Paris, France)
15.00 Identification of new familial pheochromocytoma/paraganglioma genes using Next Generation Sequencing
Alberto Cascon (Madrid, Spain)
Mesoporous silica nanoparticles for somatostatin targeted Notch activation
in animal model of pancreatic neuroendocrine cancer
15.30
Improvement of management of the patients through
cellular and animal models
Massimo Mannelli (Florence, Italy)
Paramonov V, Desai D, Mamaeva V, Rosenholm J, Rivero-Müllerand A, Sahlgren C
16.00 cofee-break
OC4 TERT promoter mutations in pancreatic endocrine tumours are frequent
in tumours from patients with hereditary syndromes
Chairs: Jerome Bertherat (Paris, France), Isabel Paiva (Coimbra, Portugal)
Vinagre J, Nabais J, Pinheiro J, Batista R,Oliveira R, Gonçalves P, Pestana A, Reis M,
Mesquita B, Pinto V, Lyra J, Godinho M, Lopes JM, Sobrinho-Simões M, Soares P
16.30 Can molecular features address the therapeutic
approach in adrenal tumours?
Eric Baudin (Villejuif, France)
10.30 coffee-break
17.00 Oral Communications
Chairs: Aldo Scarpa (Verona, Italy), José Manuel Lopes (Porto, Portugal)
OC5 The anti-proliferative effect of metformin in a model of adrenocortical carcinoma
11.00
Animal models for neuroendocrine cancer:
angiogenesis as a research paradigm
Oriol Casanovas (Barcelona, Spain)
Armignacco R, Poli G, Cantini G, Canu L, Mannelli M, Luconi M
OC6 11.30
Deciphering the antitumoural potential of stromal
somatostatin receptor signal
Corinne Bousquet (Toulouse, France)
Norepinephrine transporter (NET) as a predictive marker of response
to PI3K/mTOR inhibition in pheochromocytoma
Minaskan N, Lee M, Laitinen L, Braren R ,Pellegata N
12.00 DAXX/ATRX: ALTered telomeres as a new therapeutic gate in NETs?
Aurel Perren (Bern, Switzerland)
17.30 Meet-the-Expert: From genetics to the bedside
Mercedes Robledo (Madrid, Spain)
20.00 Meeting dinner
12.30 Lunch and poster discussion
Friday, February 19th
SESSION 4 - PITUITARY TUMOURS
Chairs: Clara Alvarez (Santiago de Compostela, Spain), Davide Carvalho (Porto, Portugal)
9.00 AIP and the somatostatin signalling in pituitary tumours
Marta Korbonits (London, UK)
9.30 Truncated sst5 receptor variants in pituitary tumours and cancer
Raul Luque (Córdoba, Spain)
10.00 Oral Communications
OC7 Bifocal intracranial germinoma presenting as adipsic diabetes insipidus
OC8 Small Cell Lung Carcinoma presenting as ophthalmoplegia due to pituitary
metastases: Case Report
Anjum MS, Frizelle IM, Thayalan R, Moore D , O’ Halloran DJ
10.30 coffee-break
Potorac J, Kreutz J, Bonneville JF, Lutteri L, Martin D, Tshibanda L, Daly A, Beckers A
Chairs: Justo Castaño (Córdoba, Spain), Helena Cardoso (Porto, Portugal)
11.00 Stem cells in pituitary... and in pituitary tumours?
Clara Álvarez (Santiago de Compostela, Spain)
11.30 Gigantism, acromegaly and GPR101
Adrian Daly (Liège, Belgium)
12.00 Keynote lecture and Farewell session. The bright and dark side
of transthyretin, a thyroxine plasma transporter
M. João Saraiva (Porto, Portugal)
Posters
Posters
THYROID TUMOURS (P01-P08)
Chairs: Barbara Jarzab (Gliwice, Poland), Fátima Borges (Porto, Portugal),
Valdemar Máximo (Porto, Portugal), Luis Raposo (Porto, Portugal)
P01 Genetic heterogeneity of Medullary Thyroid Carcinoma
Romei R, Ciampi R, Tacito A, Casella F, Ugolini C, Porta M, Torregrossa L,
Basolo F, Elisei R
P02 Methimazole induced agranulocytosis side effect-not always
a bad effect: case report
Soare I, Sirbu A , Betivoiu M, Fica S
P03 Prevalence of BRAF V600E mutation in Romanian thyroid tumors patients
Schipor S, Manda D, Vladoiu S, Caragheorgheopol A, Giulea C, Ilie DM, Badiu C
P04 Expression of osteopontin isoforms is related with thyroid cancer
growth and invasion
Ferreira L,Tavares C, Ana Pestana A, Catarina Leite C, Catarina Eloy C, Rios E,
Celestino R, Batista R, Sobrinho-Simões M, Gimba E, Soares P
P05 Mouse model of BRAFV600E-induced papillary thyroid
carcinoma- summary of our results
Rusinek D, Swierniak M, Chmielik E, Kowal M, Kowalska M, Cyplinska R, Czarniecka A,
Piglowski W, Korfanty J, Chekan M, Jarzab M, Krajewska J, Szpak-Ulczok S,
Widłak W, Jarzab B
P06 Toxicity of tyrosine kinase inhibitors (TKIs) in the treatment of thyroid
cancer (TC) – a 10-year experience resume
Krajewska J, Kukulska A, Paliczka-Cieślik E, Handkiewicz-Junak D, Gawlik T,
Olczyk T, Kropińska A, Michalik B, Gubała E, Jarzb B
P07 The genetic screening of RET proto-oncogene in Polish population
during the past two decades
Oczko-Wojciechowska M, Sromek M, Pawlaczek A, Czetwertyńska M, Kula D,
Żebracka-Gala J, Rusinek D, Kowal M, Gubała E, Szpak-Ulczok S, Gawlik T, Zub R,
Tyszkiewicz T, Cyplińska R, Hasse-Lazar K, Wygoda Z, Krajewska J, Wiench M,
Dedecjus M, Jarzb B
P08
Medullary thyroid cancer in a RET-negative patient with a germline SDHB
mutation
Simões-Pereira J, Leite V
NEUROENDOCRINE TUMOURS (P09-P17 & P26)
Chairs: Marianne Pavel (Berlin, Germany), Oriol Casanovas (Barcelona, Spain),
Corinne Bousquet (Toulouse, France), Aurel Perren (Bern, Switzerland)
P09 Case report of ACTH- Secretingtumour of the liver
Krylov V, Dobreva E, Kharnas S, Ippolitov L, Marova E, Voronkova I
P10 A case of ectopic adrenocorticotropic hormone syndrome
in bronchial carcinoid
Vasilkova V, Mokhort T
P11 Acromegaly caused by hepatic metastasis of a pulmonary
neuroendocrine tumor
Resende E, Gouveia P, Sá M, Ferreira M, Abreu S
P12
Ectopic cushing syndrome by an aggressive gastroenteropancreatic
neuroendocrine carcinoma
Robles Lázaro C, Llamocca Portella LP, Sánchez Marcos AI, Herrero Ruiz A,
Villanueva Alvarado HS, Cabezas Andrade JS, Cáceres Martín R, Miralles García JM,
Corrales Hernández JJ
P13 Multiple Endocrine Neoplasia type 1 - retrospective analysis of 5 families
Ventura M, Melo M, Gomes L, Saraiva J, Barros L, Rodrigues D, Guelho D, Cardoso L,
Vicente N, Martins D, Oliveira D, Lages A, Carrilho F
P14 A novel germline mutation of the men 1 gene associated with multiple
endocrine neoplasia type 1 (men1 syndrome) followed over three
generations of a family
Anselmo J, Sousa I, Cavaco B, Leite V, César R
P15 Post-pancreatectomy persistent adult Nesidioblastosis:
follow-up of 24 years
Almeida R, Santos AP, Teixeira Gomes J, Bastos Lima, Bacelar C
P16 Insulinomas at São João Hospital between 1980 and 2015
Neves JS, Lau E, Oliveira J, Oliveira AI, Freitas P, Carvalho D
P17 Aggressive multifocal angiomyxoma - a surgical challenge
Lambrescu I, Blaga C, Stefan C, Soare I, Fica S
P26 MetS, abdominal obesity and fasting glucose are risk factors
for differentiated digestive NETs: a case-control study
Santos AP, Santos AC, Castro C, Raposo L, Torres I, Henrique R, Monteiro MP, Cardoso H
SPEDM - SOCIEDADE PORTUGUESA
DE ENDOCRINOLOGIA DIABETES E METABOLISMO
ADRENOCORTICAL TUMOURS, PHEOCHROMOCYTOMA
AND PARAGANGLIOMA (P18-P20)
Chairs: Alberto Cascon (Madrid,Spain), Massimo Mannelli (Florence, Italy),
Eric Baudin (Villejuif, France)
P18 Massive bilateral pheocromocitoma: a rare case
Martins D, Baptista C, Rodrigues D, Melo M, Cardoso LM,
Vicente N, Oliveira D, Ventura M, Lages A, Carrilho F
P19 Recurrent adrenal pheochromocytoma: a benign condition?
Sousa Lages A, Oliveira P, Rodrigues D, Costa G, MartinsMJ, Furtado E, Oliveira J,
Vicente N, Cardoso L, Oliveira D, Martins D, Ventura M, Carrilho F
P20 The importance of fully investigating adrenal incidentaloma – two
pheochromocytoma cases
Oliveira D, Paiva S, Paiva I, Rodrigues D, Guelho D, Cardoso L, Vicente N, Martins D,
Lages A, Ventura M, Carrilho F
Rua Fernando Vicente Mendes, N.º 1B, 1º Dto
1600-892 Lisboa • Portugal
TEL: (+351) 217 210 548 / FAX: (+351) 217 210 566
E-mail: [email protected]
www.spedm.org
SEEN
C/ Villalar, 7 bajo - interior dcha.
28001, Madrid • España
TEL: 914 313 294
www.seen.es
IPATIMUP
INSTITUTE OF MOLECULAR PATHOLOGY
AND IMMUNOLOGY OF THE UNIVERSITY OF PORTO
Rua Dr. Roberto Frias s/n - 4200-465 Porto • Portugal
Phone: 225 570 700 / Fax: 225 570 799
E-mail: [email protected]
www.ipatimup.pt
CENTRO HOSPITALAR DO PORTO
HOSPITAL STO ANTÓNIO
Largo Prof. Abel Salazar - 4099-001 Porto
Tel: 222 077 500
www.chporto.pt
EUROPEAN SOCIETY OF ENDOCRINOLOGY
PITUITARY TUMOURS and OTHERS (P21-P25)
Chairs: Marta Korbonits (London, UK), Raul Luque (Córdoba, Spain),
Clara Álvarez (Santiago de Compostela, Spain), Adrian Daly (Liège, Belgium)
P21 Pituicytoma: a rare tumor
Oliveira D, Gomes L, Rodrigues D, Belo F, Rebelo O, Paiva S, Moreno C, Guelho D,
Balsa AM, Rodrigues N, Cardoso L, Martins D, Carrilho F
P22 Hypothyroidism and thyroid autoimmunity in metastatic renal cell
carcinoma patients treated with sunitinib: 2 years follow up of long
survivors from a sigle centre experience
Pani F, Scartozzi M, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S
P23 A rare synchronous presentation of aldosterone producing adenoma
and multifocal papillary thyroid microcarcinoma
Davitadze M, Metreveli D, Gudushauri I, Mikadze K
P24 Functional role of somatostatin receptor subtype 1 (sst1)
in prostate cancer: an in vitro approach
Pedraza-Arévalo S, Hormaechea-Agulla D, Selth LA, Castaño JP, Luque RM
P25 Metformin suppressed the proliferation of prostate cancer cells in vitro
and reduced prostate tumor growth in vivo under low-fat and,
especially, under high-fat fed conditions
Sarmento-Cabral A, López-López F, Castaño JP, Luque RM
Euro House, 22 Apex Court
Woodlands, Bradley Stoke - Bristol BS32 4JT • UK
Tel: +44 1454 642247 / Fax: +44 1454 642222
[email protected]
CONFERENCE SECRETARIAT
Acropole, Lda
Paula Nora | Joana Inês
Rua de Gondarém, 956 r/c - 4
150-375 Porto
Telefs: 226 199 683 | 968 900 358
[email protected] | [email protected]
SPONSORS
Leading global
endocrine journals
Publishing cutting-edge basic science
IMPACT
FACTOR:
3.718
IMPACT
FACTOR:
3.081
www.try-jme.org
www.try-joe.org
IMPACT
FACTOR:
4.805
www.try-erc.org
Global readership
Fast publication times: average first
decision in less than 3 weeks
World-class editorial boards
Author and reader tools such as
article-level metrics, including Altmetric
Free journal-based learning programme
No submission fees or page charges
Check out our new
hormone-related
cancer minisite with
cross-journal content at
www.xxxxxxx.com
www.bioscicollections-hrc.com